NORPRAMIN Drug Patent Profile

When do Norpramin patents expire, and when can generic versions of Norpramin launch?

Norpramin is a drug marketed by Validus Pharms and is included in one NDA.

The generic ingredient in NORPRAMIN is desipramine hydrochloride. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the desipramine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norpramin

A generic version of NORPRAMIN was approved as desipramine hydrochloride by ACTAVIS TOTOWA on June 5^th, 1987.

Summary for NORPRAMIN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for NORPRAMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-007	Feb 11, 1982	AB	RX	Yes	No
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-004	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-006	Approved Prior to Jan 1, 1982	AB	RX	Yes	No

International Patents for NORPRAMIN

See the table below for patents covering NORPRAMIN around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	267641
France	1445454	Nouveaux dérivés d'iminodibenzyle et leur préparation

NORPRAMIN Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is NORPRAMIN and Its Current Market Status?

NORPRAMIN is the brand name for amitriptyline, a tricyclic antidepressant primarily prescribed for depression, migraine prophylaxis, and certain pain syndromes. It is marketed globally, with its patent expired in most regions, leading to widespread generic availability.

In 2022, the global market for amitriptyline was valued approximately at $200 million, with growth driven by expanding mental health awareness and chronic pain management. The compound is available in multiple formulation forms, including tablets and capsules, with off-label use for insomnia and other off-label applications.

How Does the Pharmaceutical Patent Landscape Affect NORPRAMIN?

The original patent on amitriptyline expired in the early 2000s. As a result, generic manufacturers produce low-cost equivalents, reducing NORPRAMIN's market share and profit margins. The absence of patent protection has led to a price erosion estimated at 60-70% over the past decade.

Current patent considerations shift toward secondary patents, such as formulations or delivery methods, although none significantly affect market exclusivity at this time. Regulatory exclusivity is minimal; generic entry has been complete globally.

What Are the Key Market Dynamics Influencing NORPRAMIN?

Competitive Landscape

Market competition is intense due to the widespread generic availability. Over 50 pharmaceutical companies produce amitriptyline globally, including major generics players such as Teva, Mylan, and Sandoz.

Pricing and Reimbursement

Average retail prices for amitriptyline capsules vary by region:

• United States: approximately $0.05 per 25 mg dose.
• Europe: similar, with slight variations due to local policies. Reimbursement policies favor generics, which constrains pricing power for brand-name NORPRAMIN.

Prescribing Trends

Prescription volumes increased moderately from 2015 to 2020, driven by expanded off-label use. However, newer antidepressants with better side effect profiles, such as SSRIs and SNRIs, have partially displaced amitriptyline in depression treatment.

Regulatory and Policy Factors

FDA and EMA approvals facilitate generic entry but do not restrict market share of brands with established prescriptions. Insurance reimbursement favors generics, further limiting profitability of brand-name drugs.

Emerging Therapeutic Uses

Studies on off-label applications, such as neuropathic pain and migraine prevention, sustain demand. Recent research suggests potential utility in fibromyalgia and certain sleep disorders, potentially broadening market size.

What Is the Financial Trajectory for NORPRAMIN?

Revenue Projections

Due to patent expiry and generic competition, revenue from NORPRAMIN has declined at an annual rate of 10-15% since 2010. Globally, sales diminished from $150 million in 2010 to around $45 million in 2022.

Profit Margins

Profit margins for generic amitriptyline are slim, estimated at less than 10%, owing to competitive pricing and manufacturing costs. Brand-name NORPRAMIN maintains slightly higher margins (about 15%) but faces declining sales pressures.

Market Entry and Innovation

No recent approvals of new formulations or delivery systems have occurred. R&D investments directed toward alternate indications or drug delivery methods are minimal, given the low profitability environment.

Investment Outlook

Investments in NORPRAMIN or similar legacy drugs are unlikely to generate significant returns. The focus shifts toward niche markets or combination therapies with higher theoretical margins.

How Do Future Market Trends and Innovations Impact NORPRAMIN?

The overall market for antidepressants is projected to grow modestly at 2-3% annually, driven by global mental health initiatives. However, the segment for older drugs like amitriptyline remains flat or declines slightly, with newer agents capturing market share.

Innovations in drug delivery (e.g., transdermal patches, long-acting formulations) are financially unviable for a highly commoditized drug like amitriptyline. Personalized medicine and biomarker-driven therapies have negligible immediate impact on NORPRAMIN.

What Are the Risks and Opportunities?

Risks

• Further price erosion due to increased competition.
• Decline in prescriber preference favoring newer drugs.
• Regulatory challenges related to off-label use monitoring.

Opportunities

• Exploiting niche indications with limited competition.
• Developing combination therapies or extended-release formulations.
• Targeting emerging markets where newer antidepressants are less accessible.

Key Takeaways

• NORPRAMIN is a generic, low-margin medication with declining sales driven by patent expirations and market competition.
• The drug’s market is mature, with minimal innovation activity and limited growth prospects.
• Future revenue depends on off-label uses and niche markets; broader growth unlikely.
• Margins remain constrained, and investments in R&D are unlikely to yield substantial returns.
• Regional policies and prescriber trends dictate sales performance more than new product development.

Frequently Asked Questions

1. Will NORPRAMIN regain market share?
No. The drug faces persistent generic competition and shifts toward newer antidepressants. Recovery of market share is unlikely without innovative formulations or indications.

2. Are there new patent protections or formulations planned?
No significant patent filings or approved new formulations are publicly known, limiting future exclusivity opportunities.

3. What regions offer the most growth potential?
Emerging markets with lower adoption of newer agents may present limited growth due to affordability and access issues but are highly competitive.

4. Could off-label uses expand the market?
Limited evidence could sustain some demand, but regulatory restrictions and prescriber preferences favor newer medications for primary indications.

5. Is there investment interest in legacy antidepressants like NORPRAMIN?
Interest remains low due to low margins, patent expirations, and market saturation, favoring innovation in newer drug classes.

---

[1] International Drug Price Indicator Guide, Management Sciences for Health, 2022.
[2] IQVIA Prescription Data, 2022.
[3] US Food and Drug Administration, FDA Drug Approvals, 2022.